1/10 Last #NephJC we discussed dialysis frequency in AKI-D #TenPostNephJC We sought to answer an age-old question: Is less is really more? Or less is just simply what it is….less? pubmed.ncbi.nlm.nih.gov/41201895/

Have you ever “withheld” dialysis because the patient looked good despite questionable labs? Did you feel brave or nervous? 😅 We restrict fluids, potassium, phosphorus… But what about restricting dialysis itself? Let’s talk. #NephJC

Hi everyone ! Marc here from the Philippines 🇵🇭 sharing this “imprisonment” from Jerónimos Monastery in Lisbon 🇵🇹. From historic monasteries to modern trials, let’s LIBERATE-D our thinking. Looking forward to a great discussion! No COI. #NephJC

Gracias! @dramiliflores.bsky.social #NephSky LIBERATE-D: El Resumen Visual — #NephJC www.nephjc.com/news/2025/12/14/liberate-d-el-resumen-visual

www.nephjc.com/news/... Check out the excellent #NephJC summary by @msocomd.bsky.social and @sejalplakhani.bsky.social

Join us for the last #NephJC of 2025, 12/16/25 at 9pm EST!🥳 How soon should we withhold dialysis in AKI? We're discussing the LIBERATE-D trial #NephSky This one might just change your mind 🧠🧠 Blog by @msocomd.bsky.social and @sejalplakhani.bsky.social www.nephjc.com/news/liberated-aki

Holy Mackerel! 🐟 🦜Ahoy matey! Could fish oil unlock the mysteries of increased CV mortality in ESRD? 🏴‍☠️ #NephJC Join us for a lively trawling trip 12/2/25 🛥️at 9pm EST Check out the PISCES VA by @brianrifkin.bsky.social www.nephjc.com/news/piscesva

1/10 Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC Read the article 👇 www.nejm.org/doi/10....#NephJC

T4d: That’s all partners 🤠 From here until the end of the year we will be catching up on all the late-breaking and simultaneous publications from #KidneyWk 2025. 😮‍💨 Ain’t no party like a #NephJC party!

T4c: #NephJC The rapid development of treatments for IgAN shows that nephrology can innovate like oncology and cardiology, to the benefit of our patients. Some final words of wisdom from #KidneyWk 2025

T4a: #NephJC We recently got to hear the patient voice from @jonathanpollack.bsk.social About his journey with IgAN and his excitement for a future of precision medicine while also calling for greater worldwide equity.

T3c: #NephJC The emerging evidence from APRIL/BAFF–axis trials (including VISIONARY (sibeprenlimab) & ORIGIN-3 (atacicept)) highlight how central this pathway is to the mechanisms of IgAN.

Sorry will remain a dream for a while! We may have network meta-analysis - or will have to wait for them to go generic for an NIH (if NIH will even exist) or some other public funding body to do those trials #NephJC

Same here in 🇨🇦! Related paper: jamanetwork.com/journals/jam... in @jamainternalmed.com Often RCTs include patients in our countries - but the pharma doesn’t bother with getting drugs approved outside the lucrative US market #NephJC

Hi everyone, Marc from the Philippines. Exciting times for IgAN… so much happening so fast! And the ASN FOMO is definitely real this year. No COI. #NephJC

⏰ 2 hours until chat tonight #NephJC editorial team debated for a long time...not whether to discuss @kdigo.org IgAN guidelines, but whether to do it after #Kidneywk...Have we said it well: IgAN guidelines: fresh out of press, already aging gracefully? 👀See it for yourself

Check out the awesome visual abstract by @salinesolut.bsky.social Attacking the origins of IgAN with atacicept ⚔️ www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract

Resuman Visual Revisa el resumen visual realizado por Clemens Weber @salinesolut.bsky.social . Gracias @dramiliflores.bsky.social ! www.nephjc.com/news/2025/11/17/origin-3-el-resumen-visual

Tonite 11/18/25 on #Bluesky 9pm EST We are discussing ORIGIN3 and atacicept in IgAN. APRIL, BAFF and B-cells, Oh My! (🦁🐯🐻) It's going to be Wicked good. 🧙‍♀️ #NephJC Summary by @notjustdialysis.bsky.social www.nephjc.com/news/atacicept-origin3-gtfb36

We had a lot of discussion with Barratt at his rounds on this. His point is that - early diagnosis/identification early in disease process will be key - we do have specific treatment options available now (or will soon have) - just RASi and Flozins without biopsy just masks the issue #NephJC

🎨Beautiful visual abstract by Dr Natalia Nombera @roxnonna23.bsky.social #NephJC www.nephjc.com/news/...

Hey everyone, Marc from the Philippines. Looking forward to learning tonight. No COI #NephJC

🔬for the diagnosis of glowmrulonephritis, searching for urinary acanthocytes only using bright field illumination is clearly suboptimal compared to utilizing dark field illumination or phase contrast microscopy. #UrinarySediment #UrineMicroscopy karger.com/gdz/article/...

⏩ Next #NephJC is on IgA nephropathy @kdigo.org guideline 🎨 Nice visual summary by @roxnonna23.bsky.social www.nephjc.com/news/2025/10...

Obinituzumab aka ‘Obi’ is now FDA approved for lupus nephritis finance.yahoo.com/news/fda-app... #lupus

No one should I remember being mobbed by dietitians in Argentina who are believers in this costly approach (after #ISNWCN debate) Outdated therapy. Move on and flozinate instead #NephJC

Here’s @kidneyboy.bsky.social take on that study pbfluids.com/2009/02/jour... #NephJC

🎨Beautiful visual abstract by @msocomd.bsky.social #NephJC

Check the insightful #NephJC summary by @shelliefravel.bsky.social

Hi everyone, Marc here. Looking forward to hearing everyone’s insights. No COI. #NephJC

Check at the VA for our discussion of protein diet strategies by @msocomd.bsky.social. Is restricting protein in CKD and pushing protein in ESRD #TWDFNR? www.nephjc.com/news/2025/10...

It's that time of year again 🍂🍂🍂 The #NephJC Fall pledge drive. Plese give if you are able to support our decades long mission of #FOAMed for all. #NephSky #MedSky www.nephjc.com/news/2025/9/22/nephjc-fall-pledge-drive

1/10 Welcome to #TenPostNephJC Last #NephJC we discussed about AHA/ACC 2025 Hypertension guidelines: PREVENT, Detect, Treat Didn’t catch the pulse of this one? No worries we’ll help you pressure check the 2025 AHA Hypertension Guidelines. ❤ #AHA2025 www.ahajournals.org/doi/10.1161/...

Right: more aldo, more combo meds, advocating for GLP1 as part of lifestyle change Wrong: 130=/=120, even stronger aldo rec, even stronger GLP1 rec so that insurance will cover it #nephjc

www.nejm.org/doi/full/10.... There’s some trial data on prevention of albuminuria #nephjc

Yes! Slide care of Paul Whelton at this year’s #Hypertension25 #nephjc

Even when we say we will use MRAs earlier, we don’t! We showed this. Screening is associated with WAY more MRA use (probably in part because those who think to screen are more likely to treat based on best evidence) pmc.ncbi.nlm.nih.gov/articles/PMC... #nephjc

But each has benefits like a fine wine: -The uric acid lowering of losartan -The longest half life of telmisartan -The bonus migraine prophylaxis of candesartan #nephjc

T1h Next up – Secondary HTN. The guideline provides a thorough table including 15 causes of secondary HTN with indications for additional testing and diagnostic screening tests for each. #NephJC

Check the insightful #NephJC summary by @msocomd.bsky.social and @salinesolut.bsky.social They’ve distilled a large, voluminous document into an insightful, well-written, and easily comprehensible resource.📌 You may want to bookmark this as a ready reckoner

Hey everyone, Marc here from the Philippines, currently joining in from Prague. No COI, but I have huge respect for our European colleagues who are usually with us at this wee hour—true dedication! #NephJC

❤️Check out the VA for the discussion on the AHA/ACC Hypertension Guidelines 9/16/25 at 9pm EST by @sejalplakhani.bsky.social #NephJC #NephSky #MedSky www.nephjc.com/news/2025/9/ahaacc-htnguide

Change is in the Autumn air 🌬️🍂 Join use only on #Bluesky on 9/16/25 at 9pm EST. We're discussing the 2025 ACC/AHA Hypertension Guideline Update. 🫀🫘🧠 #NephSky #MedSky www.nephjc.com/news/accaha2025-klno3

Check out the latest @kireports.bsky.social community blog from @husamjz.bsky.social Anticoagulantion in ESRD patients with atrial fibrillation: www.kireportscommunity.org/post/bleeding-clotting-and-kidney-disease-in-atrial-fibrillation-can-factor-xi-inhibitors-change-the-g

Finally, the concurrent results of the ALCHEMIST trial (www.sciencedirect.co...) also showed that spironolactone did not reduce major cardiovascular events in older, high-risk hemodialysis patients. #NephJC Infographic by @nephroseeker.medsky.socia

@nephjc.bsky.social @lastwalsh.bsky.social just presented ACHIEVE results at #ANZSN. Here’s a some details of country differences not in the main paper

And ALCHEMIST had way lower hyperkalemia (they used a lot of K binders, about 45% at baseline!) - see @nephroseeker.medsky.social VA Despite that there was no benefit! www.nephjc.com/news/2025/ne... #NephJC

The assumption was about CV risk: if DM then they are at high risk, otherwise age + ESRD = high CV risk #NephJC

Hi everyone! I’m Marc, checking in from the Philippines. Looking forward to another great discussion with you all #NephJC